Article Text

Download PDFPDF
Be wary of subsidising nicotine replacement therapy
  1. C Miller1,
  2. S Kriven1,
  3. D Rowley2,
  4. L Abram3
  1. 1Tobacco Control Research and Evaluation, The Cancer Council South Australia
  2. 2Tobacco Control Unit, South Australian Department of Human Services
  3. 3Quit SA
  1. Correspondence to:
 Ms Caroline Miller, Tobacco Control Research and Evaluation, The Cancer Council South Australia, PO Box 929, Unley 5061, South Australia;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The efficacy of nicotine replacement therapy (NRT) as a smoking cessation aid has been convincingly demonstrated in a large number of studies, including many randomised trials.1 Findings from these studies have prompted suggestions that widespread access to NRT could substantially increase quitting in a population, thereby reducing population smoking prevalence.2 Hence when NRT became available over-the-counter in pharmacies in the USA (rather than by prescription only), a large increase in quitting activity was expected.3 However, Thorndike and colleagues4 found that in Massachusetts the switching of NRT from prescription only to over-the-counter availability did not result in increases in either quitting activity in the population, the use of NRT in quit attempts, or the success of quit attempts overall. The authors argued that there are barriers to NRT use, other than having to visit a doctor to obtain a prescription. …

View Full Text